开发用于测量ANCA相关性血管炎治疗反应的复合结局工具:OMERACT 2020混合方法研究
该研究由OMERACT血管炎工作组开展,旨在为ANCA相关性血管炎(AAV)开发复合应答标准。项目遵循OMERACT复合测量方法,已完成系统文献综述和国际德尔菲调查以确定候选域/工具,并在OMERACT 2020虚拟研讨会上汇报。最终目标是开发经过验证的复合应答标准用于AAV临床试验。
要点
- OMERACT血管炎工作组正按四步法开发AAV复合应答标准。
- 已完成系统文献综述和德尔菲调查确定候选域/工具。
- 最终目标是获得验证的复合应答标准用于AAV临床试验。
核心结论
- 项目最终目标是开发经过验证的复合应答标准,用于ANCA相关性血管炎的临床试验。
研究设计与样本
- 本研究为混合方法研究,遵循OMERACT复合测量开发方法,包括选择相关域、定义高质量工具、决定评分系统方法和通过OMERACT Filter 2.1验证。
- 已完成对AAV临床试验结局测量的系统文献综述,以及在AAV患者和AAV专家临床研究者中进行的国际德尔菲调查。
主要发现
- 系统文献综述和德尔菲调查结果已在OMERACT 2020虚拟研讨会上展示,并收到关于项目下一步(包括开发评分系统方法)的反馈。
关键数值与推荐
- 系统文献综述和德尔菲调查已完成,用于为复合应答标准提供候选域/工具,这是OMERACT开发复合测量方法的前两步。
临床怎么用
- 目前尚无 validated 复合应答标准可供临床使用,项目旨在未来为AAV临床试验提供此类标准。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group aims to develop composite response criteria for ANCA-Associated Vasculitis (AAV). METHODS: The project follows the OMERACT approach for composite measures: (i) choose relevant domains; (ii) define high-quality instruments; (iii) decide on a scoring system approach; (iv) put through the OMERACT Filter 2.1 for validation. RESULTS: A systematic literature review of outcome measures used in clinical trials in AAV and an international Delphi exercise among patients with AAV and clinician-investigators with expertise in AAV have been completed to inform the candidate domains/instruments for the composite response criteria, which are the first two steps in the OMERACT approach for developing composite measures. Results of the systematic literature review and Delphi were presented at the OMERACT 2020 virtual workshop, and feedback was received on the next steps of the project, including the development of a scoring system approach. CONCLUSION: The ultimate goal of this project is to develop validated composite response criteria for use in clinical trials of AAV.
引用
- Quinn KA, Monti S, Christensen R, et al. Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Semin Arthritis Rheum. 2021. PMID: 34274125. doi:10.1016/j.semarthrit.2021.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。